Previous close | 2.7400 |
Open | 2.8700 |
Bid | 0.0000 x 1400 |
Ask | 0.0000 x 1000 |
Day's range | 2.8000 - 2.8800 |
52-week range | 2.0000 - 11.9500 |
Volume | |
Avg. volume | 26,920 |
Market cap | 223.31M |
Beta (5Y monthly) | 0.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6940 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.25 |
MARSEILLE, France, June 23, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that its investor relation team will participate in the following upcoming investor conference:
MARSEILLE, France, June 03, 2022--Innate Pharma announces IPH5201 Phase 2 study in lung cancer
MARSEILLE, France, May 20, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took place on May 20, 2022, in Marseille. All resolutions were voted on in accordance with the Executive Board’s recommendations.